writer：Rui Wang, Han Wang, Guohua Jiang, Yanfang Sun, Tianqi Liu, Lei Nie, Amin Shavandi, Khaydar E. Yunuso
keywords：Microneedles, serum uric acid, transdermal delivery
source：期刊
specific source：Biomaterials Science
Issue time：2022年

Allopurinol (AP) is widely used to treat hyperuricemia which may cause severe side effects after oral administration. Alternative means for the treatment of hyperuricemia are demanded to simultaneously facilitate drug absorption, patient compliance, and fewer side effects. In this study, a new polymer microneedles (MNs) system was developed for transdermal delivery of AP on acute hyperuricemic mice. This study aims to achieve the controllable regulation of serum uric acid (SUA) levels with fewer side effects compared with oral administration. The matrix of polymer MNs consisted of polyvinylpyrrolidone (PVP) and polycaprolactone (PCL), in which the rapid dissolution of PVP offers a rapid dissolution of AP into the blood and the biodegradability of PCL resulting in a sustainable drug release behavior. An in vivo study demonstrated that the AP-loaded MNs system can effectively reduce the SUA levels as oral administration with lower side effects, which will conducive to reducing the adverse reactions and improving the bioavailability of AP. This MNs-mediated strategy can facilitate transcutaneous hyperuricemia treatment and provide a new alternative for the exploration of clinical treatment of hyperuricemia and improvement of patient compliance.